ascendis pharma glp-1 receptor agonist medications Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug YUVIWEL (navepegritide), approved by the

All weight loss injections carry some risk of nausea, though rates vary from 24-44% depending on the medication and dose

Less frequent injections could significantly improve adherence for people who find weekly injections burdensome

report no conflicts of interest

Mounjaro (tirzepatide): Patients taking the 15 mg dose lowered their hemoglobin A1C (a way to measure blood sugar over time) by 2.4% in some studies

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies, eliminating middlemen, brand markups, and distribution costs associated with brand-name drugs

For many, a New Year brings resolutions, hope, and excitement